References
- Stanek G, Wormser GP, Gray J, Strle F. Lyme borreliosis. Lancet 379, 461–473 (2012).
- Steere AC, Livey I. Lyme disease vaccines. In: Vaccines (6th Edition). Plotkin SA, Orenstein WA, Offit PA, (Eds). Elsevier, PA, USA, 1122–1132 (2012).
- Sigal LH, Zahradnik JM, Lavin P et al. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium. N. Engl. J. Med. 339, 216–222 (1998).
- Steere AC, Sikand VK, Meurice F et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group. N. Engl. J. Med. 339, 209–215 (1998).
- Gross DM, Forsthuber T, Tary-Lehmann M et al. Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science 281, 703–706 (1998).
- Steere AC, Drouin EE, Glickstein LJ. Relationship between immunity to Borrelia burgdorferi outer-surface protein A (OspA) and Lyme arthritis. Clin. Infect. Dis. 52(Suppl. 3), s259–s265 (2011).
- Poland GA. Vaccines against Lyme disease: What happened and what lessons can we learn? Clin. Infect. Dis. 52(Suppl. 3), s253–s258 (2011).
- Plotkin SA. Correcting a public health fiasco: The need for a new vaccine against Lyme disease. Clin. Infect. Dis. 52(Suppl. 3), s271–s275 (2011).
- Wressnigg N, Pollabauer EM, Aichinger G et al. Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double–blind, randomised, dose–escalation phase I/II clinical trial. Lancet Infect. Dis. (2013).
- Livey I, O'Rourke M, Traweger A et al. A new approach to a Lyme disease vaccine. Clin. Infect. Dis. 52(Suppl. 3), s266–s270 (2011).
- Abbott A. Lyme disease: uphill struggle. Nature 439, 524–525 (2006).
- Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin. Infect. Dis. 47, 401–409 (2008).
- Nadelman RB, Hanincova K, Mukherjee P et al. Differentiation of reinfection from relapse in recurrent Lyme disease. N. Engl. J. Med. 367, 1883–1890 (2012).
- Schoen RT, Sikand VK, Caldwell MC et al. Safety and immunogenicity profile of a recombinant outer-surface protein A Lyme disease vaccine: clinical trial of a 3-dose schedule at 0, 1, and 2 months. Clin. Ther. 22, 315–325 (2000).
- Barrett PN, Portsmouth D, Ehrlich HJ.Tick-borne encephalitis vaccines. In: Vaccines (6th Edition). Plotkin SA, Orenstein WA, Offit PA, (Eds). Elsevier, PA, USA, 773–788 (2012).
Websites
- Centers for Disease Control and Prevention. Notices to Readers: Final 2011 Reports of Nationally Notifiable Infectious Diseases. www.cdc.gov/mmwr/pdf/wk/mm6132.pdf
- WHO. Lyme borreliosis in Europe: influences of climate and climate change, epidemiology, ecology and adaptation measures. www.euro.who.int/document/E89522.pdf
- US FDA. Prescribing Information. LYMErix (TM) Lyme Disease Vaccine (Recombinant OspA). www.fda.gov/ohrms/dockets/ac/01/briefing/3680b2_03.pdf